AIM ImmunoTech (AIM) has the following price history information. Looking back at
AIM historical stock prices for the last five trading days, on September 13, 2019, AIM opened at $1.94, traded as high as $1.94 and as low as $1.85, and closed at $1.87. Trading volume was a total of 15.70K shares. On September 16, 2019, AIM opened at $1.81, traded as high as $1.89 and as low as $1.81, and closed at $1.84. Trading volume was a total of 53.30K shares. On September 17, 2019, AIM opened at $1.85, traded as high as $1.85 and as low as $1.75, and closed at $1.77. Trading volume was a total of 30.20K shares. On September 18, 2019, AIM opened at $1.77, traded as high as $1.80 and as low as $1.62, and closed at $1.66. Trading volume was a total of 70.60K shares. On September 19, 2019, AIM opened at $3.36, traded as high as $3.60 and as low as $2.09, and closed at $2.20. Trading volume was a total of 8.90M shares.
AIM Historical Stock Prices By Date:
Below, we examine the compound annual growth rate — CAGR for short — of an investment into AIM ImmunoTech shares, starting with a $10,000 purchase of AIM, and working forward through the historical stock price information to today.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/21/2009 |
|
| End date: |
09/19/2019 |
|
| Start price/share: |
$2.01 |
|
| End price/share: |
$2.20 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
9.45% |
|
| Average Annual Total Return: |
0.91% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$10,948.18 |
|
| Years: |
10.00 |
|
 |
| Date |
Open |
High |
Low |
Close |
Volume |
| 09/13/2019 |
$1.94 |
$1.94 |
$1.85 |
$1.87 |
15.70K |
| 09/16/2019 |
$1.81 |
$1.89 |
$1.81 |
$1.84 |
53.30K |
| 09/17/2019 |
$1.85 |
$1.85 |
$1.75 |
$1.77 |
30.20K |
| 09/18/2019 |
$1.77 |
$1.80 |
$1.62 |
$1.66 |
70.60K |
| 09/19/2019 |
$3.36 |
$3.60 |
$2.09 |
$2.20 |
8.90M |
|
|
| Hemispherx Biopharma is an immuno-pharma company, focused on the research and development of therapeutics to treat several types of cancers, as well as immune-deficiency disorders. Co. has a foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. Co.'s products include Ampligen®, a drug of macromolecular ribonucleic acid molecules, and Alferon N Injection®, a drug also known as a chemical entity that contains an active moiety |
| Date |
Close |
| 09/13/2019 | $1.87 |
| 09/16/2019 | $1.84 |
| 09/17/2019 | $1.77 |
| 09/18/2019 | $1.66 |
| 09/19/2019 | $2.20 |
Historical Stock Price
